FDA Approved: ZARONTIN — Supplemental Application (Parke-Davis Div of Pfizer Inc)

View source ↗

Summary

FDA approved a supplemental application for Zarontin (ethosuximide) from Parke-Davis Div. of Pfizer Inc., indicating approved changes to the existing labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Absence Seizures

Drugs mentioned

• ZARONTIN (ethosuximide)

Snippet

SUPPL AP for ZARONTIN (ETHOSUXIMIDE)